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Background: Abiraterone Acetate (AA) is approved for the treatment of mCRPC after
failure of androgen deprivation therapy in whom chemotherapy is not yet clinically
indicated and for treatment of mCRPC progressed during or after docetaxel-based
chemotherapy regimen. The aim of this study is to evaluate the role of early PSA decline
for detection of therapy success or failure in mCRPC patients treated with AA in post
chemotherapy setting.
Patients and Methods: We retrospectively evaluated 87 patients with mCRPC treated
with AA. Serum PSA levels were evaluated after 15, 90 days and then monthly. The
PSA flare phenomenon was evaluated, according to a confirmation value at least 1 week
apart. The primary endpoint was to demonstrate that an early PSA decline correlates
with a longer progression free survival (PFS) and overall survival (OS). The secondary
endpoind was to demonstrate a correlation between better outcome and demographic
and clinical patient characteristics.
Results: We have collected data of 87 patients between Sep 2011 and Sep 2014. Early
PSA response (≥50% from baseline at 15 days) was found in 56% evaluated patients and
confirmed in 29 patients after 90 days. The median PFS was 5.5 months (4.6–6.5) and
themedian OSwas 17.1months (8.8–25.2). In early responders patients (PSA RR≥ 50%
at 15 days), we found a significant statistical advantage in terms of PFS at 1 year, HR
0.28, 95%CI 0.12–0.65, p = 0.003, and OS, HR 0.21 95% CI 0.06–0.72, p = 0.01. The
results in PFS at 1 years and OS reached statistical significance also in the evaluation at
90 days.
Conclusion: A significant proportion (78.6%) of patients achieved a rapid response in
terms of PSA decline. Early PSA RR (≥50% at 15 days after start of AA) can provide
clinically meaningful information and can be considered a surrogate of longer PFS and
OS.
Keywords: prostate cancer, prognostic factors, PSA detection, metastatic castration resistant prostate cancer,
abiraterone acetato, overall survival
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INTRODUCTION
Prostate cancer growth depend on signaling from the activated
androgen receptor (AR). Nearly 90% of all patients with
metastatic prostate cancer initially respond to castration-induced
androgen deprivation. Unfortunately, this therapeutic response
is not lasting, with a median duration of 18–24 months, after
which the tumor progresses despite hormonal castration levels,
so we define a prostate cancer as castration-resistant (CRPC).
Some authors reported that the AR remains activated and
plays an important role during the progression of metastatic
CRPC (mCRPC; Zhu et al., 2010; D’Aniello et al., 2014; Zhang
et al., 2015). Several mechanisms are involved such as: genomic
amplification and over expression of AR, gain of function
mutations of AR, up-regulation of AR enhancer elements,
alterations in androgen transport, increased synthesis of extra
gonadal androgens, abnormalities in AR co-activators and co-
regulators, ligand-independent trans-activation of AR by growth
factors or cytokines, and AR splice variants (Rathkopf and Scher,
2013). Docetaxel was the first systemic therapy to show an
improvement in overall survival (OS) in patients with mCRPC
(Petrylak et al., 2004; Tannock et al., 2004). Recently, different
agents with different mechanisms of action have demonstrated
efficacy, and four new drugs (cabazitaxel [CBZ], sipuleucel-
T, enzalutamide [ENZ], and abiraterone acetate [AA]) were
approved for mCRPC treatment (de Bono et al., 2010, 2011;
Kantoff et al., 2010; Fizazi et al., 2012; Scher et al., 2012; Bahl et al.,
2013; Di Lorenzo et al., 2013). Among these, AA is an inhibitor
of the androgen biosynthesis enzyme CYP17 (17-a-hydroxylase
and C17, 20-lyase) and it has been approved for treatment
of mCRPC after failure of androgen deprivation therapy in
whom chemotherapy is not yet clinically indicated and for the
treatment of mCRPC progressed on or after a docetaxel-based
chemotherapy regimen (de Bono et al., 2011; Fizazi et al., 2012).
The COU-AA 301 trials demonstrated a prolonged OS in AA–
prednisone group than in the placebo–prednisone group.Median
time to PSA progression was 8.5 months in the AA group vs. 6.6
months in the placebo group with a confirmed advantage in the
AA treatment (Marra et al., 2008; Facchini et al., 2010; de Bono
et al., 2011; Fizazi et al., 2012; Zhou et al., 2014).
In this context, it is required the validation of predictive
markers of response. PSA decline after cytotoxic chemotherapy
has been identified as a valid surrogate for OS and PSA
progression-free survival at 3 months, in fact its reductions may
reflect reductions in tumor burden. Many retrospective reports
confirmed that patients with mCRPC who had a 50% decline
in PSA from baseline, had a survival improvement, compared
with patients who did not achieve 50% reduction in PSA (Smith
et al., 1998; Scher et al., 1999; Small et al., 2002; Halabi et al.,
2013). However, to date, its role as surrogate OS endpoints
remains uncertain, especially in the course of non-cytotoxic
therapies such as new-generation hormonal agents for still few
data in this setting. Recent evidences demonstrate that tubulin-
targeting drugs (docetaxel) cause cytoplasmic AR sequestration
ex vivo (Jiang and Huang, 2010; Zhu et al., 2010; Buonerba
et al., 2011; Mezynski et al., 2012) and in circulating tumor
cells (Buonerba et al., 2011), significant down-regulation of AR
and PSA expression, and nuclear accumulation of the fork head
transcription factor family member FOXO1. This last is a potent
repressor of AR function (Gan et al., 2009; Kuroda et al., 2009;
Franco et al., 2011) and suggest the strong evidence that the
antitumor activity of docetaxel is also associated with disruption
of AR signaling. These data could support the hypothesis of a
cross-resistance between docetaxel and AA. The activity of AA,
similarly, also appears to differ according to its sequencing with
docetaxel (Caraglia et al., 2005; Mezynski et al., 2012; Loriot et al.,
2013). The aim of our retrospective analysis is to demonstrate
that an early PSA decline correlates with longer progression free
survival (PFS) and OS in order to validate this parameter as an
early predictive marker of AA response, in order to exclude from
treatment patients non-responders, therefore reducing costs, and
serial determinations of PSA.
PATIENTS AND METHODS
This retrospective study enrolled 87 patients at three sites in Italy
(National Cancer Institute of Naples–Fondazione G. Pascale,
Oncological Institute of Candiolo and Santa Chiara Hospital in
Trento) with histologically confirmed metastatic prostate cancer,
who became refractory to hormonal therapy, and progressed after
chemotherapy (treated with at least one line docetaxel containing
regimen). All patients received AA (1000mg orally once daily
at least 1 h before or 2 h after meal, with prednisone 10mg
daily). Each cycle of treatment was 28 days long. All patients
maintained androgen deprivation with a serum testosterone level
of 50 ng per decilitre or less (≤2.0 nmol per liter). During AA
treatment, patients monthly had a check of their hematological
parameters. PSA value was recorded after 15 days from the start
of therapy and then monthly. Tumor assessment with computed
tomography (CT) and/or bone scan was performed at baseline
and then every 3 months or as clinical indicated. Baseline ECG
and Echocardiogram were obtained and further cardiac work-up
was performed if indicated. Treatment could be continued until
disease progression, which was defined based on the Prostate
Cancer Working Group II criteria, death or unacceptable
toxicity. In case of biochemical progression only during the
first 3 months of treatment, evidence of radiological/metabolic
progression was required to stop the therapy. Patients were
stratified according to variables considered potential predictors
of better outcome included: baseline ECOG performance status
score (0 or 1 vs. 2), age (≤70 vs. >70 years), Gleason score
(≤7 vs. >7), previous prostatectomy (yes or no), previous
curative radiotherapy (yes or no), duration of previous ADT for
metastatic disease, number of previous chemotherapy regimens
(1 vs. >1), extent of disease (visceral vs. non-visceral disease),
previous cumulative docetaxel dose expressed in mg/m2 (≤675
vs.>675mg/m2), duration of AA treatment. Table 1 summarizes
Baseline Demographic and Clinical Patient Characteristics.
Early PSA response rate (PSA RR) was assessed 15 days
after the start of treatment, and then after 12 weeks (according
with PCWG 2). Early PSA RR (at 15 days) was defined as
a ≥50% reduction from baseline, stratifying patients as early
responders or early non-responders PSA and PSA Progression
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TABLE 1 | Baseline Demographic and Clinical Patients’ Characteristics.
All subjects 87
N. pts/total (%)
AGE
Median (range) − years 72.2 (48–84)
>70 years 52/87 (59.8)
ECOG
0–1 75/87 (86.2)
>1 12/87 (13.8)
GLEASON
≤7 43/87 (34.5)
>7 48/87 (55.1)
Missing data 9/87 (10.3)
PREVIOUS THERAPIES
Prostatectomy
Yes 41/87 (47.1)
No 46/87 (52.9)
CURATIVE RADIOTHERAPY
Yes 24/87 (27.6)
No 59/87 (67.8)
Missing data 4/87 (4.6)
DURATION OF PREVIOUS ADT FOR METASTATIC DISEASE
<2.5 years 43/87 (49.4)
≥2.5 years 41/87 (47.1)
Missing data 3/87 (3.4)
PREVIOUS CYTOTOXIC CHEMOTHERAPY
1 60/87 (68.9)
>1 27/87 (31.1)
TOTAL PREVIOUS DOCETAXEL DOSE (mg/m2)
≤675 mg/m2 50/87 (57.5)
>675 mg/m2 36/87 (41.4)
Missing data 1/87 (1.1)
TREATMENT DURATION WITH AA
≤7 months 54/87 (62.1)
>7 months 22/87 (25.3)
Missing data 11/87 (12.6)
EXTENT OF DISEASE
No visceral disease 79/87 (90.8)
Visceral disease 8/87 (9.1)
for an increase of 25% or 5 ng/ml absolute value from baseline
(Table 2). Our aim is to demonstrate that an early PSA decline
correlate with longer PFS and OS in order to validate this
parameter as an early predictive marker of response to AA,
excluding patients non-responders and therefore reducing costs
treatment related and serial determinations of PSA.
STATISTICAL ANALYSES
We record the time from the initial treatment with AA to
progression as PFS; OS was defined as the time from the last
follow-up to death. Univariate analysis for PFS and OS were
calculated according to the Kaplan-Meier method. Statistical
differences between curves were calculated using log-rank test.
TABLE 2 | PSA value and response.
PSA
Median baseline (range)—ng/dl 332.2 (1–3922)
PSA RR at 15 days- N. pts/total (%)
No of patient evaluable 75/87
≥50% 42/75 (56)
<50% 17/75 (22.7)
PSA progression 16/75 (21.3)
PSA RR at 90 days-
No of patient evaluable 29/42
≥50% 13/29 (44.8)
<50% 16/29 (55.2)
We analyzed PSA response rates computing a percentage-
reduction at 15 days and 90 days through the following formula:
[(a – b)/b∗100] where a) baseline PSA; b) 15 days PSA or 90
days PSA; the proportion of patients with a decrease of ≥50%
in the PSA concentration from the baseline PSA value were
considered the best category. The Cox proportional hazards
model was used to test the effect of PSA response rates on survival
outcomes in multivariate analyses. Hazard ratios (HRs) and 95%
CIs were estimated, adjusting for age and the PSA response rates
were investigated as independent factors (Figure 1). Stratified
analyses were carried out to assess whether PSA response rates
were consistent across subgroups. A p < 0.05 was considered
significant. Statistical analysis was performed using SPSS (version
21; SPSS, Inc., Chicago, IL).
RESULTS
Between Sep 2011 and Sep 2014, 87 patients’ records were located,
all had sufficient follow-up information and 75/87 were eligible
for correlation analysis. TheTable 1 summarize baseline patients’
characteristics. Median serum PSA value at baseline was 332.2
ng/dl (range: 1–3922). PSA decline was observed in 78.6% (59/75)
of patients. Early PSA response (≥50% from baseline at 15 days)
was found in 56% (42/75) evaluated patients. At 90 days after
starting AA, 29/42 patients confirm a PSA value of response.
Confirmed PSA RR ≥ 50% was found in 31% (13/29). In early
responders patients (PSA RR ≥ 50% at 15 days), we found a
significant statistical advantage in terms of PFS at 1 year, HR
0.28, 95%CI 0.12–0.65, p = 0.003, and OS, HR 0.21 95% CI
0.06–0.72, p = 0.01 (Figure 1). The median OS was 17.1 months
(8.8–25.2). In this group of early PSA responders, we evaluated
the confirmed PSA RR at 90 days. The results in PFS at 1 years
and OS (Figure 2) reached statistical significance, HR: 0.23 95%
CI 0.07–0.77, p = 0.02 and HR: 0.14 95% CI 0.03–0.70, p = 0.02,
respectively (Tables 2, 3). The proportion of patients alive at 1
year was 88% (n = 15) in PSA ≥ 50% and 12% (n = 5) in PSA
< 50%; no patients were observed without progression at 1 year
in both categories. Our analysis showed a positive correlation
between OS and duration of AA treatment in early responders.
Patients treated formore than 7months with AA had a significant
longer survival, HR 0.27 95% CI 0.13–0.57, p= 0.001.
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FIGURE 1 | Kaplan-Meier estimates of Overall Survival according to PSA response rate* at 15 days. *Defined as the proportion of patients with a decrease
of ≥50% in the PSA concentration from the basline PSA value to 15 days.
Patients with more than 70 years old had a longer OS, HR
0.03 95% CI 0.01–0.80, p = 0.032. The improvement in OS
was achieved also in patients with one previous chemotherapy
treatment, HR 0.11 95% CI 0.01–0.95, p = 0.045. Early
responders who received a cumulative dose of docetaxel ≤675
mg/m2 confirmed a statistical advantage in OS, HR 0.07 95% CI
0.007–0.8, p= 0.032. Previous hormonal therapy duration (≥2.5
months) for metastatic setting correlated with longer OS, HR
0.06 95% CI 0.004–0.99, p = 0.05. These results are summarized
in Tables 4, 5. Concerning the other stratification, we do
not found a significant statistical correlation in terms of PFS
and OS.
DISCUSSION
mCRCP is a heterogeneous disease in which AR remains
activated and plays an important role during the progression
of mCRPC. Several mechanisms contribute to continue AR
signaling in mCRPC (Rathkopf and Scher, 2013). A significant
percentage of patients with mCRPC that progresses in the
course or after docetaxel are potential candidates to additional
treatments in order to be able to increase OS (de Bono et al., 2011;
Fizazi et al., 2012). Until few years ago, there were few therapeutic
opportunities, formally recognized, with no outcome in terms of
survival. To date there are at least three approved drugs such as
AA, CBZ and ENZ (Bubley et al., 1999; de Bono et al., 2010, 2011;
Fizazi et al., 2012; Scher et al., 2012; Bahl et al., 2013; Di Lorenzo
et al., 2013). The most important question mark remains how
to choose the best treatment sequencing and if there are some
early response marker to guide clinical choice. To make effective
use of secondary therapies there is a definite need to predict
clinical or biological markers for early identification of non-
responders patients, whomay benefit from alternative treatments
thus allowing a reduction in costs. All recent phase III trials have
used as criteria for assessing the efficacy of some drugs, those
established by the Prostate Cancer Working Group 2 (PCWG 2)
criteria (Scher et al., 2008). These criteria define the efficacy of
drugs in phase II trials and demonstrate whether the therapeutic
effects observed justified further evaluation in large-scale phase
III trials. These criteria do not reflect the clinical reality and
are often difficult to apply. Many prognostic factors predict OS
after docetaxel therapy (including pre-treatment variables such
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FIGURE 2 | Kaplan-Meier estimates of Overall Survival according to PSA response rate at 90 days*. *Subgroup of 29 patients with confirmation of response
obtained at 15 days included in the analysis of PSA response at 90 days.
TABLE 3 | Results of multivariate analysis in early PSA responders (≥50%).
Variable Median OS (months)
and (95% CI)
HR* (95% CI) p-value
ADVANTAGE IN OS
PSA RR at 15 days 16.6 (0.1–38.4) 0.21 0.06–0.07 0.01
PSA RR at 90 days 20.6 (6.4–34.7) 0.14 0.03–0.70 0.02
Advantage in PFS
at 1 year
Median PFS (months)
and (95% CI)
PSA RR at 15 days 4.6 (2.3–6.9) 0.28 0.12–0.65 0.003
PSA RR at 90 days 5.6 (5.3–5.8) 0.23 0.07–0.77 0.02
*Multivariate Cox model adjusted for terms of age and center.
as bone pain, visceral metastases, performance status, anemia,
bone scan progression, and PSA) but none of these variables is
predictive of responses to new hormonal treatments (Armstrong
and Febbo, 2009). Although several prostate cancer–associated
antigens have been identified, PSA is the most commonly used
(Miles et al., 2008). Many studies found that a PSA decline of
> 50%, following chemotherapy, was highly prognostic because
of is an early marker of drug activity and a potential surrogate
of OS (Bubley et al., 1999; Petrylak et al., 2006; Armstrong
et al., 2007a; Hussain et al., 2009; Caffo et al., 2012; Kijima
et al., 2012). It is known that PSA can reflect the burden of
disease in men with mCRPC. Decline in PSA value can reflect
a reduction in disease burden and a potential clinical benefit
with cytotoxic chemotherapy or hormonal agents (Vollmer et al.,
TABLE 4 | Univariate Analysis: median follow-up survival (Overall).
Variables Median (months) p-value*
AA treatment duration <0.0001
<7 months 7.2
≥7 months 27.7
Age 0.5
<70 years 17.9
≥70 years 12.4
Previous chemotherapy treatment 0.4
≤1 line 3.5
>2 7.2
Cumulative dose of Docetaxel 0.8
≤675 mg/m2 17.06
>675 mg/m2 16.6
Previous hormonal duration therapy 0.5
<2.5 months 12.4
≥2.5 months 17.5
*Log-rank test.
1998; Scher et al., 1999; Armstrong et al., 2007b, 2012). There is
a direct relationship between AR activity and PSA production.
Hence, PSA could be a valid clinical marker to minimize patient
exposure to ineffective therapy. Other retrospective studies based
on clinical experience such as the Caffo et al. one (Caffo et al.,
2014), aimed at identifying factors predicting primary resistance
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TABLE 5 | Advantage in OS for early PSA RESPONDERS (≥50%).
Variables HR* 95% CI. p-value
AA TREATMENT DURATION
<7 months r.c.
≥7 months 0.27 0.13–0.57 0.001
AGE
<70 years r.c.
≥70 years 0.03 0.01–0.80 0.032
PREVIOUS CHEMOTHERAPY TREATMENT
≤1 line 0.11 0.01–0.95 0.045
>2 r.c.
CUMULATIVE DOSE OF DOCETAXEL
≤675 mg/m2 0.07 0.007–0.8 0.032
>675 mg/m2 r.c.
PREVIOUS HORMONAL DURATION THERAPY
<2.5 months 0.06 0.004–0.99 0.05
≥2.5 months r.c.
*Multivariate Cox model adjusted for age; r.c., reference category.
to new-generation hormonal agents. In this study, the role of
these parameters was clearly demonstrated only in the cumulative
analysis of patient treated with ENZ while in the AA group
was not confirmed. Another study, presented at ASCO GU 2015
(Rescigno et al., 2015) conducted on 124 patients who had
received AA post-docetaxel demonstrated that the PSA response
of≥30% at 4 weeks from the baseline was significantly correlated
with OS (P < 0.001) in multivariate analyses including other
established prognostic factors in mCRPC (ECOG PS, albumin,
PSABL, ALP, LDH, Hemoglobin). In our study, the aim was
to evaluate an early PSA RR, defined as ≥50% reduction from
baseline at 15 days after started AA, and confirmed at 90 days
(according PWCG2) as surrogate of increased PFS at 1 year and
prolonged OS. In early responders patients we found a significant
statistical advantage in terms of PFS at 1 year, HR 0.28, 95% CI
0.12–0.65, p = 0.003, and OS, HR 0.21 95% CI 0.06–0.72, p =
0.01. AA treatment lasting more than 7 months, one previous
chemotherapy treatment, a cumulative dose of docetaxel ≤675
mg/m2 and previous hormonal therapy duration ≥2.5 years,
correlated with longer OS.
A PSA expression correlated with the activation of AR. PSA
decline seemed to be an excellent surrogate for survival in AR-
driven tumor but not in AR-independent one. Docetaxel caused
cytoplasmic AR sequestration ex vivo (Jiang and Huang, 2010;
Zhu et al., 2010; Buonerba et al., 2011; Mezynski et al., 2012) and
in circulating tumor cells (Darshan et al., 2011) with significant
down-regulation of AR and PSA expressions, so the PSA value
seemed not to be useful in CRPCAR-independent (Caraglia et al.,
2005; Kuroda et al., 2009; Loriot et al., 2013; Caffo et al., 2015).
Conversely, recent evidences have demonstrated the molecular
heterogeneity of CRPC in terms of re-expression of the AR for
genomic amplification, over-expression and up regulation after
docetaxel treatment. The persistent activation of AR signal in
all stages of CRPC has led to consider PSA decline as a valid
predictivemarker of treatment response and a surrogate of longer
OS in apparently AR-independent CRPC (Armstrong et al., 2012;
Rathkopf and Scher, 2013).
In any case the treatment with AA has been successfully
continued even in those who did not register a reduction in early
PSA with a median follow-up survival of 27.7 months in patients
with a duration treatment of more than 7 months Probably this
will lead us to distinguish patients in two groups with different
sensitivity to the drug.
CONCLUSION
In conclusion, these results have suggested that early PSA RR can
provide clinically meaningful information and can be considered
a surrogate of longer PFS and OS. In this context, early PSA
RR may represent an early and easily obtainable predictive
marker of response to AA. This is a retrospective analysis with
a limited number of patients so further investigation with a
larger cohort and prospective setting should be performed in the
future.
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